Table 1 Characteristics of the patients included in the analysis (n = 1,465,020)

Yes

1,260,785 (86.1%)

No

107,486 (7.3%)

Contraindicated

55,025 (3.8%)

Not indicated

41,724 (2.9%)

Age (years), median (IQR)

65.5 (51.6–75.4)

63.7 (47.7–75.0)

66.1 (51.3–76.9)

62.8 (47.0–74.0)

Male

714,183 (56.7)

59,990 (55.8)

32, 152 (58.4)

24,725 (59.3)

Female

546,133 (43.3)

47,469 (44.2)

22, 853 (41.6)

16,989 (40.7)

Admission diagnosis

Head trauma with or without multi trauma

12,438 (79.4)

1,471 (9.4)

1,425 (9.1)

325 (2.1)

Cardiac arrest

25,350 (85.6)

2,506 (8.5)

927 (3.1)

819 (2.8)

Intracerebral haemorrhage

4,943 (66.1)

873 (11.7)

1,502 (20.1)

158 (2.1)

Subarachnoid haemorrhage

5,211 (78.9)

525 (7.9)

789 (11.9)

83 (1.3)

Stroke

8,814 (75.7)

1,153 (9.9)

1,388 (11.9)

290 (2.5)

Cardiovascular disease

304,248 (24.0)

25,201 (23.3)

8,819 (15.9)

15,968 (38.0)

Respiratory disease

193,278 (15.3)

16,387 (15.2)

4,027 (8.2)

6,102 (14.5)

Sepsis

89,523 (7.1)

7,882 (7.3)

4,700 (8.4)

2,239 (5.3)

Pre-existing chronic conditions

Chronic respiratory disease

93,399 (7.4)

7,521 (7.0)

3,549 (6.4)

2,671 (6.4)

Chronic cardiovascular disease

112,346 (8.9)

9,313 (8.7)

6,547 (11.9)

3,391 (8.1)

Chronic renal failure

41,055 (3.3)

3,963 (3.7)

2,570 (4.7)

1,558 (3.7)

Chronic liver disease

18,523 (1.5)

2,407 (2.2)

3,531 (6.4)

647 (1.5)

Immunosuppressive disease

26,801 (2.1)

2,050 (1.9)

1,629 (3.0)

510 (1.2)

Metastatic cancer

50, 100 (4.0)

3,130 (2.9)

2,085 (3.8)

889 (2.1)

APACHE III score, median (IQR), %

48.0 (35.0–64.0)

47.0 (33.0–66.0)

54.0 (38.0–75.0)

46.0 (32.0–62.0)

APACHE III predicted mortality, mean (SD),%

12.5 (18.6)

14.4 (21.7)

21.2 (25.4)

11.8 (20.0)

ANZROD (%), mean (SD)

7.4 (15.5)

9.4 (19.1)

15.2 (23.6)

7.5 (17.1)

Length of hospital stay, median (IQR), d

8.1 (4.5–14.7)

6.6 (2.8–12.9)

7.8 (3.7–15.9)

6.5 (2.8–11.5)

Hospital mortality

89,891 (7.1)

11,285 (10.5)

8,723 (15.8)

3,376 (8.1)